Press Releases Calliditas Therapeutics AB Nasdaq

Equities

CALT

US13124Q1067

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-21 pm EDT			5-day change	1st Jan Change
21.5 ^USD	-2.27%		-4.82%	-16.49%

05:12pm	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	MT
May. 20	European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

In Person & Virtual R&D Day: The Anti Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action	May. 16	PU
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action	May. 16	AQ
Calliditas Therapeutics : Invitation to the presentation of Calliditas´s interim report January - March 2024	May. 16	PU
Invitation to the presentation of Calliditas's interim report January - March 2024	May. 16	AQ
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm	May. 15	AQ
Notice of annual general meeting of Calliditas Therapeutics AB (publ)	May. 15	AQ
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China	May. 14	AQ
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib	May. 06	AQ
Calliditas Therapeutics' 2023 Annual Report Published	Apr. 24	AQ
Calliditas Announces Positive NefIgArd Open Label Extension Results	Apr. 24	AQ
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024	Apr. 18	AQ
Calliditas Therapeutics to Attend Conferences in April	Apr. 09	AQ
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires	Apr. 08	AQ
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment	Apr. 08	AQ
Calliditas Therapeutics : February 21, 2024 Year-end report 2023 (Presentation)	Mar. 14	PU
Calliditas announces an additional seven year orphan drug exclusivity Period for TARPEYO	Mar. 07	AQ
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®	Mar. 06	AQ
Calliditas Therapeutics to Attend Investor Conferences in March	Mar. 04	AQ
Calliditas Therapeutics to Attend Investor Conferences in March	Mar. 01	AQ
Calliditas Year-end report, January - December 2023	Feb. 21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Calliditas Therapeutics AB Nasdaq

Equities

CALT

US13124Q1067

Press Releases

Filters